Clinical Trials Logo

Clinical Trial Summary

The investigators will re-investigate 150 children studied extensively in the past. 100 of these children were born to mothers prescribed methadone during their pregnancy because of opiate dependency, and 50 were comparison children who were not exposed to drugs. These children were investigated when they were newborn babies, and again when they were six months old, and a quarter of the drug-exposed babies had problems with their eyesight, whilst very few of the comparison children has eyesight problems. The investigators would like to see whether the eyesight problems are still present in the children now that they are older. Because they are older, more detailed testing can be undertaken which will help to understand how drug exposure in the womb may have affected their eyesight. The investigators will recruit new, comparison children to the study to match the number of comparison children with the number of drug-exposed children. The findings will be relevant and important when advising mothers on drug use - both prescribed and illicit - when they are pregnant.


Clinical Trial Description

Multiple researchers across the world over many decades have noted eyesight problems in children born to mothers who use drugs during pregnancy. From our earlier work on this group of children, we have detailed knowledge of which drugs each mother used, making this group of children uniquely important for understanding the consequences of drug use during pregnancy. Although methadone use in the UK is dropping as heroin misuse falls, there is currently an international epidemic of babies being born to mothers using illicit or prescribed opioid drugs (e.g. methadone, heroin, opiate-based painkillers). These babies may be at risk of the same eyesight problems as this Scottish cohort. Knowing the longer-term consequences and disseminating the findings to relevant international clinical groups could help to alleviate the consequential damage, through better information for mothers and through better and prompter management of affected children.

The study is planned to run for 2 years. It is anticipated that a maximum of 65 drug-exposed children (out of the original 100) will attend, and will therefore aim to also investigate 65 comparison children, as many as possible of whom will belong to the original cohort of 50 comparison children.

Testing will take place in the Children's Clinical Research Facility (CRF), on the campus of the Queen Elizabeth University Hospital and Royal Hospital for Children, Glasgow. A CRF paediatric nurse will recruit, coordinate and administrate the study. They will manage the child's progress through the assessment session, measure height, weight and head circumference, document demographic, social and educational details from the child's carer, and will apply two questionnaires to the carers. Eyesight tests will be done by a specialist paediatric orthoptist, and will include acuity (the smallest letter correctly identified), stereoacuity (perception of depth) and looking for squints or nystagmus (shaking or wobbling of the eyes).

Highly specialised eye tests (eye movement recordings and visual evoked potentials) will also be undertaken.

If any abnormalities are noted from these tests, the child will be given eyedrops to dilate their pupils. All children will be seen by a paediatric ophthalmologist who will look at the back of their eyes, and check whether they need glasses, or whether their glasses are correct. A medical history will be taken. If any problems are noted during the visit (e.g. visual, medical, social), the child will be referred to relevant services after discussion with their carer.

The data will be added to the existing database for these children, and the test results correlated with the results found at birth and at six months, and with the any known drug exposure of each child. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03603301
Study type Observational
Source NHS Greater Glasgow and Clyde
Contact
Status Enrolling by invitation
Phase
Start date July 1, 2017
Completion date June 2020

See also
  Status Clinical Trial Phase
Completed NCT03596138 - Reliability and Reproducibility of Automated Angular Measurement in Strabismus
Completed NCT04432181 - Comparison of Deviation Types Among Astigmatic Children With Or Without Amblyopia
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Recruiting NCT04770519 - Genetic Studies of Strabismus, Nystagmus, and Associated Disorders
Completed NCT01512355 - The Effect of Dexmedetomidine on Decreasing Emergence Agitation and Delirium in Pediatric Patients Undergoing Strabismus Surgery N/A
Completed NCT00461656 - Povidone-iodine Antisepsis for Strabismus Surgery Phase 4
Completed NCT00535938 - MDs on Botox Utility (MOBILITY) N/A
Completed NCT01109459 - Multimodal Physician Intervention to Detect Amblyopia N/A
Not yet recruiting NCT06035757 - The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery Phase 4
Completed NCT01430247 - Vision Screening for the Detection of Amblyopia N/A
Recruiting NCT04416776 - Validation of the Utility of Strabismus Intelligent Diagnostic System
Recruiting NCT04353960 - The Alaska Oculocardiac Reflex Study
Terminated NCT02246556 - Dichoptic Virtual Reality Therapy for Amblyopia in Adults Phase 1
Completed NCT01726842 - Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner N/A
Completed NCT00001143 - Development of the Eye Motor System During the First 7 Months of Life in Infants With and Without a Family History of Cross-Eye N/A
Completed NCT03806270 - Hydroxyzine Dihydrochloride Premedication is a Necessity for Strabismus Surgery
Completed NCT04303832 - Exercise Interventions of Eye Muscles Post Strabismus Surgery N/A
Recruiting NCT05425589 - Adjustable Strabismus Surgery N/A
Completed NCT00559234 - Potential Research Participants for Future Studies of Inherited Eye Diseases N/A
Completed NCT02570555 - Strabismus Surgery and Driving Ability